NCN. V. Cherepanova

N. V. Cherepanova

*This is an algorithmically generated author record based on publicly available information.

N. V. Cherepanova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Features of PET/CT Description with 18F-Fluoroestradiol in Patients with Estrogen-Positive Breast Cancer

    by A. V. Parnas, A. I. Pronin, D. A. Ryabchikov, P. E. Tulin, A. S. Subbotin, V. S. Ilyakov, N. V. Cherepanova, Yu. I. Prokofiev

    Purpose: To study possible errors in the interpretation and analysis of PET/CT studies with 18F-FES performed in patients with estrogen receptor-positive breast tumors.Material and methods: Data PET/CT with 18F-FES from 140 PET patients were retrospectively analyzed from 2017 to 2023. The study included patients with histologically confirmed estrogen receptor-positive breast cancer, before the start of specific treat­ment, as well as when progression is detected or if a metastatic process is suspected at the initial examination stage.Results: Recommendations are given for the assessment and interpretation of various changes detected during PET/CT with 18F-FES in patients with estrogen receptor-positive breast cancer, which may cause difficulties in analyzing the results of the study.Conclusion: Although the PET/CT with 18F-FES in our country has not yet been widely introduced into clinical practice, in some institutions the study is carried out within the framework of scientific protocols and in complex cases of differential diagnosis. For a more correct interpretation of PET/CT with 18F-FES should take into account the clinical and morphological features in each clinical case.

  • Open Access

    PET/CT with 18F-Fluoroestradiol in First Diagnosed Breast Cancer. A Pilot Study

    by A. V. Parnas, A. S. Subbotin, A. I. Pronin, P. E. Tulin, D. A. Ryabchikov, V. S. Ilyakov, N. V. Cherepanova, O. V. Mekhedova

       Purpose: To evaluate the informativity of PET/CT with 18F-FES in determining estrogen receptor (ER) positivity in breast tumor tissue, as well as in regional lymph nodes or distant metastatic foci.   Material and methods: The data of 30 patients who underwent PET/CT with 18F-FES performed at the stage of primary diagnosis were retrospectively analyzed. The study included patients before the start of specific treatment or on the background of neoadjuvant hormone therapy, with previously determined expression of ER according to the results of IGC. 14 patients underwent 18F-FDG PET/CT with 2–7 days difference between both PET/CT.   Results: In our study, the mean SUVmax value in the primary tumor focus was 4.8, the lowest SUVmax = 1.61, and the highest SUVmax = 18.86. 18F-FES accumulation considered suspicious for metastatic lesion in axillary lymph nodes on the affected side was detected in 16 patients (56 %), mean SUVmax = 5.2, lowest SUVmax = 0.99, highest SUVmax = 11.54. On subsequent histological examination, tumor changes in axillary lymph nodes were confirmed in 16/16 patients.   Conclusion: PET/CT with 18F-FES is a diagnostic method for noninvasive evaluation of ER expression in tumor foci, which can complement the data of traditional diagnostic methods and has a significant clinical potential. In our study, the results of PET/CT with 18F-FES coincided with the data of immunohistochemical study in 100 % of cases.